# A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

> **NCT02857270** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 210 (actual)

## Conditions studied

- Advanced Cancer
- Metastatic Melanoma
- Metastatic Non-small Cell Lung Cancer
- Colorectal Cancer

## Interventions

- **DRUG:** LY3214996
- **DRUG:** Midazolam
- **DRUG:** Abemaciclib
- **DRUG:** Nab-paclitaxel
- **DRUG:** Gemcitabine
- **DRUG:** Encorafenib
- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT02857270
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-09-29
- **Primary completion:** 2021-02-10
- **Final completion:** 2022-10-24
- **Target enrollment:** 210 (ACTUAL)
- **Last updated:** 2022-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02857270

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02857270, "A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02857270. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*